Stock listing

Editas Medicine, Inc.

Selected listing: A2AC4K · LS · EUR · DE

Editas Medicine, Inc. (Lang & Schwarz: A2AC4K), Health Technology. Latest release Sep 8, 2026: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer.

A2AC4K:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A2AC4K
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

About Editas Medicine, Inc.

Editas Medicine, Inc. is a public biotechnology company based in America, focused on developing transformative genomic medicines. Editas is engaged in advancing its proprietary gene-editing technology to address various genetic diseases.

Latest news from Editas Medicine, Inc.

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

September 8, 2026

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

August 5, 2026

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

August 4, 2026

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

May 28, 2026

Editas Medicine Announces Proposed Public Offering

May 26, 2026

All Editas Medicine, Inc. news →

Events

Replays

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call
Wed, Aug 07, 2024 · 08:00 AM ET
Watch
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call
Wed, May 08, 2024 · 08:00 AM ET
Watch
Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call
Wed, Feb 28, 2024 · 08:00 AM ET
Watch

Research Editas Medicine, Inc.

Editas Medicine, Inc. company profile

View the public company page for Editas Medicine, Inc. on 6ix.

Editas Medicine, Inc. news

Read company news and market updates connected to Editas Medicine, Inc..

Editas Medicine, Inc. investor events

Find investor webinars, events, and replay context for Editas Medicine, Inc..